Coeptis Therapeutics (NASDAQ:ZSQR) Shares Gap Down – What’s Next?
by Sarita Garza · The Markets DailyCoeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR – Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $14.71, but opened at $13.11. Coeptis Therapeutics shares last traded at $13.15, with a volume of 5,389 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen downgraded Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics currently has a consensus rating of “Sell”.
Check Out Our Latest Analysis on Coeptis Therapeutics
Coeptis Therapeutics Price Performance
The company’s fifty day moving average is $12.35 and its two-hundred day moving average is $12.81. The firm has a market capitalization of $706.65 million, a price-to-earnings ratio of -5.45 and a beta of -0.22. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01.
Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. The business had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.
Institutional Investors Weigh In On Coeptis Therapeutics
A number of institutional investors have recently made changes to their positions in ZSQR. Steward Partners Investment Advisory LLC lifted its stake in Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares during the period. Yorkville Advisors Global LP bought a new position in Coeptis Therapeutics during the third quarter worth about $140,000. Marshall Wace LLP acquired a new position in shares of Coeptis Therapeutics during the 4th quarter worth about $259,000. State Street Corp grew its position in shares of Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares during the period. 13.88% of the stock is owned by institutional investors and hedge funds.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.